Science matched to
your indication.
Fidēs brings deep imaging expertise and a growing network of specialist scientists to each therapeutic area ensuring the right scientific approach for every study.
The right expertise for
every indication.
Early-phase imaging is not generic. The endpoints that matter, the modalities that best capture biological change, and the biomarkers worth tracking are all indication-specific. Fidēs combines in-house scientific depth with a curated KOL network to bring genuinely relevant expertise to each program whether you are working in GI, oncology, women’s health or metabolic disease.
Gastroenterology
Gastroenterology
Fidēs' native scientific home. A decade of GI imaging expertise across IBD and motility disorders. With proprietary tools for quantifying movement and function beyond standard sMARIA and MaRIA scoring.
Oncology
Oncology | GI & Solid tumor
Augmented response endpoints and scientific rigour for early-phase solid tumour programs where standard RECIST measures do not tell the full story.
Women’s Health
Women’s Health | Endometriosis, Adenomyosis, PMOS, uterine cancer, Infertility and fibroids
Bringing advanced imaging and quantified endpoints to the Female Pelvis.
Rheumatology
Rheumatology | Sclerosis, Scleroderma
Structural and functional imaging support for early-phase programs.
Where would you like to go next?
Capabilities
From study design through to final report: see how Fidēs supports every stage of the imaging lifecycle in early-phase clinical development.
View CapabilitiesAperis
Real-time visibility of imaging data, annotations and analyses throughout your study built for how scientists actually work in early development.
Explore AperisCase studies
See how our imaging approach has shaped go / no-go decisions across GI, oncology and beyond in real early-phase programs.
Browse Case Studies